Lakeway, TX -- (SBWIRE) -- 02/14/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
Concho Resources Inc. (NYSE:CXO) shares decreased 2.29% and closed at $93.96 in the last trading session. Coverage of Concho Resources Inc. ( CXO ) has been initiated by analysts at Credit Suisse with a Neutral rating and a price target of $94 a share
Additionally, the company, on Feb. 7, provided a 2012 operational update, including full-year production, year-end estimated proved reserves and updated 2013 production guidance. Concho’s production for 2012 totaled 29.8 MMBoe (18.0 MMBbls of crude oil and 70.6 Bcf of natural gas), a 26% increase over 2011 production of 23.6 MMBoe and represents achievement of the upper-end of the Company’s 2012 full-year guidance.
How Should Investors Trade CXO After The Latest Earnings Report? Find Out Here
Accuray Incorporated (NASDAQ:ARAY) shares fell 2.06% to $4.28. The company, on Feb. 6, reported second quarter total consolidated GAAP revenue of $77.8 million and total non-GAAP revenue of $77.7 million. Consolidated GAAP net loss attributable to stockholders for the second quarter of fiscal 2013 was $29.2 million, or $0.40 per share, compared to $10.4 million, or $0.15 per share, for the second quarter of the prior year. Non-GAAP net loss for the second quarter of fiscal 2013 was $22.0 million or $0.30 per share compared to $7.1 million or $0.10 per share for the second quarter of the prior year.
Additionally, the company announced that its president and chief executive officer, Joshua H. Levine, is scheduled to present at the Leerink Swan Global Healthcare Conference in New York on Thursday, February 14, 2013 at 9:20 a.m. EST/6:20 a.m. PST.
Is ARAY a Buy After The Solid Earnings? Get Free Trend Analysis Here
Shares of Constellations Brands (STZ) soar 17.7% premarket after a revised agreement between Anheuser-Busch InBev and Grupo Modelo sets up the company to distribute Modelo brands in the U.S. A key battle will be between Corona and Bud Light Lime.
Is STZ a Buy After The Solid Earnings? Get Free Trend Analysis Here
Teva (TEVA) is facing a bill of up to $2.1B for selling generic versions of Pfizer's (PFE) heartburn drug Protonix before its U.S. patent exclusivity expired in 2011. Teva had already provisioned $670M in Q3 and said this week that the figure could go up by another $1.4B. A trial for Pfizer's claim for damages is due to start in June, while Teva also plans to appeal a jury verdict that upheld Protonix's patent.
Get Latest News, Updates and Reports For Free On TEVA Here
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)